We’re thrilled to announce a major milestone in our mission to democratize access to robotics in rehabilitation. The ABLE Exoskeleton is now officially approved for use with a wide clinical variety. Expanded Indications: Serving a Wider Range of Patients 🔹The ABLE Exoskeleton is now indicated for gait rehabilitation for people
Discover the latest features of the ABLE Exoskeleton designed to improve neurorehabilitation, enhance gait training and support clinicians in therapy.
We are incredibly grateful for the progress made in 2025! Here we’ve summarised this year’s significant milestones!
El Exoesqueleto ABLE ha sido incorporado en 6 hospitales públicos de Catalunya dentro de una compra centralizada del Departament de Salut, a través del Plan de Recuperación, Transformación y Resiliencia financiado por la Unión Europea-NextGenerationEU.
We’re excited to announce three new features of the ABLE exoskeleton, designed hand-in-hand with therapists and users.
We are excited to announce a new official distributor: Bayber, who will commercialize our robotic exoskeleton in Portugal. This partnership marks another important milestone in our mission to democratize access to robotic rehabilitation across Europe.
